Acute Myeloid Leukemia Clinical Trials in Seattle, Washington

31 studies are recruiting for acute myeloid leukemia in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

   Study ASTX030-01 is a multi-phase study comprising of Phases 1-3 Monotherapy arms, and Phase 1 and Phase 2 Combination Therapy arms. Phase 1 Monotherapy consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (o…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Seattle Cancer Care Alliance, Seattle, Washington

   Locations

   71 in total

   Run by

   Taiho Oncology, Inc.

   See if you can join NCT04256317 on ClinicalTrials.gov

2. Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

   This phase I/II trial finds the best dose, side effects and how well giving venetoclax in combination with cladribine, cytarabine, granulocyte colony-stimulating factor, and mitoxantrone (CLAG-M) in treating patients with acute myeloid leukemia and high-grade myeloid neoplasms. Venetoclax may stop …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   University of Washington

   See if you can join NCT04797767 on ClinicalTrials.gov

3. A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

   The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic sy…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   8 in total

   Run by

   Chordia Therapeutics, Inc.

   See if you can join NCT05732103 on ClinicalTrials.gov

4. Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

   This phase II trial investigates two strategies and how well they work for the reduction of graft versus host disease in patients with acute leukemia or MDS in remission. Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell transplant helps stop the growth of cel…

   Stage

   Phase 2

   Ages

   1 to 60

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Locations

   3 in total

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT03970096 on ClinicalTrials.gov

5. PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

   A phase 1, open-label, non-randomized study enrolling pediatric and young adult patients with relapsed or refractory CD33+ leukemia with and without prior history of allogeneic hematopoietic cell transplantation, to examine the safety and feasibility of administering an autologous T cell product th…

   Stage

   Phase 1

   Ages

   Up to 30

   Site

   Seattle Children's Hospital, Seattle, Washington

   Run by

   Seattle Children's Hospital

   See if you can join NCT05105152 on ClinicalTrials.gov

6. Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

   Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Fred Hutchinson Cancer Center, Seattle, Washington

   Locations

   5 in total

   Run by

   Vincerx Pharma, Inc.

   See if you can join NCT06034275 on ClinicalTrials.gov